Vigil Neuroscience Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-92.17	-84.26	-82.64	-68.31	-43.28	-57.09
Depreciation & Amortization	0.48	0.45	0.4	0.08	0.03	-
Asset Writedown & Restructuring Costs	-	-	-	-	-	41.85
Loss (Gain) From Sale of Investments	-1.02	-1.56	-1.49	-	-	-
Stock-Based Compensation	10.28	10.12	8.9	5.48	2.09	0.52
Other Operating Activities	1.44	1.41	1.36	0.93	1.18	2.66
Change in Accounts Payable	0.15	0.02	0.01	-2.48	2.35	2.21
Change in Unearned Revenue	20.01	20.01	-	-	-	-
Change in Other Net Operating Assets	2.6	2.59	3.09	-0.85	-1.71	-0.51
Operating Cash Flow	-58.21	-51.22	-70.36	-65.15	-39.35	-10.36
Capital Expenditures	-0.35	-0.01	-0.67	-0.92	-0.2	-
Sale (Purchase) of Intangibles	-	-	-	-	-	-1
Investment in Securities	24.63	8.77	-64.46	-	-	-
Investing Cash Flow	24.28	8.76	-65.14	-0.92	-0.2	-1
Total Debt Issued	-	-	-	-	-	10
Long-Term Debt Repaid	-	-	-0.02	-0.04	-0.04	-
Net Debt Issued (Repaid)	-	-	-0.02	-0.04	-0.04	10
Issuance of Common Stock	18.03	9.68	0.91	140.62	0.04	0
Other Financing Activities	-	-	-	20.68	-1.89	-
Financing Cash Flow	37.84	29.49	0.89	161.26	107.75	59.66
Net Cash Flow	3.9	-12.97	-134.61	95.19	68.2	48.3
Free Cash Flow	-58.57	-51.23	-71.04	-66.07	-39.55	-10.36
Free Cash Flow Per Share	-1.33	-1.26	-1.83	-2.08	-25.82	-7.68
Levered Free Cash Flow	-26.6	-21.95	-40.06	-41.43	-22.5	-
Unlevered Free Cash Flow	-26.6	-21.95	-40.06	-41.43	-22.5	-

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q